The Interaction of Human Serum Albumin with a Novel Antidiabetic Agent - SU-118

Journal of Pharmaceutical Sciences

Volumn 93, Issue 4, 2004, Pages 1039-1046

  Zhong, Wenying ^a   Wang, Yuchun ^a   Yu, Jun Sheng ^a   Liang, Yingqiu ^a   Ni, Kunyi ^b   Tu, Shuzi ^b  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Absorption spectroscopy; Antidiabetic agent; Drug interactions; Fluorescence spectroscopy; Human serum albumin; Protein binding; Thermodynamics

Indexed keywords

ANTIDIABETIC AGENT; SERUM ALBUMIN; SU 118; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE SPECTROSCOPY; HUMAN; HYPOGLYCEMIA; THERMODYNAMICS; ULTRAVIOLET SPECTROSCOPY;

EID: 1842534284     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20005     Document Type: Article

References (33)

1. He MH, Larte DC. 1992. Atomic structure and chemistry of human serum albumin. Nature 358:209-215.
2. Carter DC, Ho JX. 1994. Structure and ligand binding properties of human serum albumin. Adv Protein Chem 45:153-203.
3. Muller WE, Wollert U. 1979. Human serum albumin as a "silent receptor" for drugs and endogenous substances. Pharmacology 19:56-59.
4. Caravan P, Cloutier NJ, Greenfield MT. 2002. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 124:3152-3162.
5. Neault JF, Tajmir-Riahi HA. 1998. Interaction of cisplatin with human serum albumin. Drug binding mode and protein secondary structure. Biochim Biophys Acta/Protein Struct Mol Enzymol 1384:153-159.
6. Trynda-Lemiesz L, Kozlowski H. 1996. Some aspect of the interaction of adriamycin with human serum albumin. Bioorganic Med Chem 4:1709-1713.
7. 2+ antagonist, to serum albumin: A fluorescence study. J Pharm Sci 83:674-676.
8. Sellers EM, Koch-Wester J. 1997. Albumin structure, function, and uses. New York: Pergamon Press, pp 159-182.
9. Sudlow G, Birkett DJ, Wide DN. 1976. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmcol 12:1052-1061.
10. Fehske KJ, Muller WE, Wollert U. 1981. The location of drug binding sites in Human Serum Albumin. Biochem Pharmacol 30:687-692.
11. Yamasaki K, Maruyama T, Kragh-Hansen U. 1996. Characterization of Site I on human serum albumin: Concept about the structure of a drug binding site. Biochim Biophys Acta 1295:147-157.
12. Farnsworth NR, Cordell GA. 1976. A review of some biologically active compounds isolated from plants as reported in the 1974-1975 literature. J Nat Prod 29:420-455.
13. Shani J, Glodschmied A, Joseph B. 1974. Hypoglycaemic effect of trigonella forenum graecum and lupinus termis (leguminosae) seeds and their major alkaloids in alloxan-diabetic and normal rats (J). Arch Int Pharmacodyn. 210:27-37.
14. Shen ZF, Chen QM, Liu HF, Xie MZ. 1989. The hypoglycemic effect of clausenacoumarine. Acta Pharm Sini 24:391-392.
15. Han Y, Tu SZ, Zhou WF. 2002. Synthesis and bioactivity of coumarin-6-sulnylureas. J Chin Pharm Univ 33:93-97.
16. Zia H, Price JC. 1976. Binding study of tetracyclines to human serum albumin using difference spectropgotometry. J Pharm Sci 65:226-230.
17. Purcell M, Neault JF, Riahi T. 2000. Interaction of taxol with human serum albumin. Biochim Biophys Acta 1478:61-68.
18. Pyle AM, Rehmann JP, Meshoyrer R, Kumar CV, Turro NJ, Barton JK. 1989. Mixed-ligand complexes of Ruthenium (II): Factors govering binding to DNA. J Am Chem Soc 111:3051-3058.
19. Suldow G, Brikett DJ, Wade DN. 1975. The characterization of two specific drugs binding on human serum albumin. Mol Pharmacol 11:824-832.
20. Wanwimolruk S, Birkett DJ, Brooks PM. 1983. Structural requirements for drug binding to site II on human serum albumin. Mol Pharmacol 24:458-463.
21. Scattchard G. 1949. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660-672.
22. Russeva V, Mihailova D. 1996. Modelling of indometacin and diclofenac sodium binding to the molecule of human serum albumin. Arzneimittelforschung/Drug Res 46:288-292.
23. Polet H, Steinhardt J. 1968. Binding-induced alterations in ultraviolet absorption of native serum albumin. Biochemistry 7:1348-1356.
24. Trynda-Lemiesz L, Keppler BK, Koztowski H. 1999. Studies on the interaction between human serum albumin and imidazolium [trans-tetrachlorobis (imidazol) ruthenate (III). J Inorg Biochem 73:123-128.
25. Chen GZ, Huang XZ. 1990. Methods of fluorescence analysis. Beijing: Science Press, pp 115-119.
26. Lakowica JR, Weber G. 1973. Quenching of fluorescence by oxygen, a probe for structural fluctuations in macromolecules. Biochemistry 12:4161-4170.
27. Ware WR. 1962. Oxygen quenching of fluorescence in solution: An experimental study of the diffusion process. J Phys Chem 66:455-458.
28. Miller JN. 1979. Recent advances in molecular luminescence analysis. Proc Anal Div Chem Soc 16:203-208.
29. Zhu J, Tong SY. 1996. A study on the reaction between fluorescein and protein. Chem J Chin Univ 17:539-542.
30. Panjehshahin MR, Bowmer CJ, Yates MS. 1991. Effect of valproic acids, its unsaturated metabolites and some structurally related fatty acid on the binding of warfrain and dansylsarcosine to human albumin. Biochem Pharmacol 41:1227-1233.
31. Panjehshahin MR, Yates MS, Bowmer CJ. 1992. A comparison of drug binding sites on mammalian albumins. Biochem Pharmacol 44:873-879.
32. Muller N, Lapicque F, Drelon E. 1994. Binding sites of fluorescent probes on human serum albumin. J Pharm Pharmacol 46:300-304.
33. Ross PD, Subramanian S. 1981. Thermodynamic of protein association reactions: forces contributing to stability. Biochemistry 20:3096-3102.